The proposed extracellular model of Cr(III) action in this report is upstream of IRS1, a therapeutic target of White and others [7,8], and may lend itself to small-molecule therapeutic strategies for diabetes and other metabolic conditions [1]. Here, IRS1 is linked to diabetes mellitus.